ENDRA Life Sciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on August 14, 2023. The filing serves to disclose two primary events: the announcement of financial results for the quarter ended June 30, 2023, and the submission of a de novo application to the U.S. Food and Drug Administration (FDA) for the Company's Thermo-Acoustic Enhanced Ultrasound technology.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not detailed in the body of this Form 8-K.
Material Changes and Operational Updates
- Financial Results: The Company announced its financial results for the quarter ended June 30, 2023, via a press release (Exhibit 99.1).
- Regulatory Milestone: The Company submitted a de novo application to the FDA for its Thermo-Acoustic Enhanced Ultrasound technology (Exhibit 99.2).
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook statements, or detailed risk factors. It notes that the information regarding financial results and the FDA application is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2023 financial figures including revenue, net loss, and cash position.
- Review Exhibit 99.2 (Press Release) for details regarding the scope and status of the FDA de novo application.
- Verify the Company's cash runway and burn rate based on the detailed financial statements referenced in the press release.
- Monitor subsequent filings for updates on the FDA application status and any changes to the Company's capital structure.